François‐Xavier Mathy

953 total citations
16 papers, 654 citations indexed

About

François‐Xavier Mathy is a scholar working on Cellular and Molecular Neuroscience, Dermatology and Pharmaceutical Science. According to data from OpenAlex, François‐Xavier Mathy has authored 16 papers receiving a total of 654 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Cellular and Molecular Neuroscience, 5 papers in Dermatology and 5 papers in Pharmaceutical Science. Recurrent topics in François‐Xavier Mathy's work include Advancements in Transdermal Drug Delivery (5 papers), Dermatology and Skin Diseases (5 papers) and Drug Transport and Resistance Mechanisms (4 papers). François‐Xavier Mathy is often cited by papers focused on Advancements in Transdermal Drug Delivery (5 papers), Dermatology and Skin Diseases (5 papers) and Drug Transport and Resistance Mechanisms (4 papers). François‐Xavier Mathy collaborates with scholars based in Belgium, United Kingdom and United States. François‐Xavier Mathy's co-authors include Véronique Préat, Richard H. Guy, Yogeshvar N. Kalia, Aarti Naik, Ingo Alberti, Christophe Herkenne, Roger K. Verbeeck, Rhys Whomsley, M. Strolin Benedetti and Jean‐Baptiste Watelet and has published in prestigious journals such as Neurology, Annals of the New York Academy of Sciences and Pharmaceutical Research.

In The Last Decade

François‐Xavier Mathy

16 papers receiving 637 citations

Peers

Countries citing papers authored by François‐Xavier Mathy

Since Specialization

Citations

This map shows the geographic impact of François‐Xavier Mathy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by François‐Xavier Mathy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites François‐Xavier Mathy more than expected).

Fields of papers citing papers by François‐Xavier Mathy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by François‐Xavier Mathy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by François‐Xavier Mathy. The network helps show where François‐Xavier Mathy may publish in the future.

Co-authorship network of co-authors of François‐Xavier Mathy

This figure shows the co-authorship network connecting the top 25 collaborators of François‐Xavier Mathy. A scholar is included among the top collaborators of François‐Xavier Mathy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with François‐Xavier Mathy. François‐Xavier Mathy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti‐seizure medication: Levetiracetam case study 2023 ·Pharmacology Research & Perspectives ·Annie Delaunois, François‐Xavier Mathy, (unknown), Vitalina Gryshkova, (unknown), (unknown), (unknown), (unknown), Simon Hebeisen, Elisa Passini, Blanca Rodríguez, Jean‐Pierre Valentin	3
2	Evaluation and Application of a PET Tracer in Preclinical and Phase 1 Studies to Determine the Brain Biodistribution of Minzasolmin (UCB0599) 2023 ·Molecular Imaging and Biology ·Joël Mercier, Massimo Bani, Anny‐Odile Colson, Massimiliano Germani, (unknown), Christophe Plisson, Mickaël Huiban, Graham E. Searle, François‐Xavier Mathy, Richard Nicholl, Christian Otoul, Johan W. Smit, (unknown), (unknown), R. P. Maguire	3
3	Phase 1/1b Studies of UCB0599, an Oral Inhibitor of α‐Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease 2022 ·Movement Disorders ·Johan W. Smit, (unknown), (unknown), Laurent Detalle, François‐Xavier Mathy, (unknown), (unknown), Massimiliano Germani, (unknown), (unknown), Massimo Bani, (unknown), Just Genius	34
4	Results from a Phase 1b Study of UCB0599, an Orally Available, Brain-penetrant Inhibitor of Alphasynuclein (ASYN) Misfolding in People Living with Parkinson’s Disease (PD) (2025) 2021 ·Neurology ·Just Genius, (unknown), Laurent Detalle, (unknown), (unknown), (unknown), (unknown), François‐Xavier Mathy, (unknown), Johan W. Smit, Johannes Streffer, (unknown)	4
5	Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions 2019 ·European Journal of Pharmaceutical Sciences ·Jean‐Marie Nicolas, Hugues Chanteux, Johan Nicolaï, (unknown), (unknown), (unknown), (unknown), (unknown), François‐Xavier Mathy, (unknown), Eric Helmer	3
6	Pharmacokinetics and metabolism of [¹⁴C]-tozadenant (SYN-115), a novel A2a receptor antagonist ligand, in healthy volunteers 2016 ·Xenobiotica ·(unknown), François‐Xavier Mathy, Pierre Boulanger, Stephen English, (unknown), Christopher Kenney, (unknown), Armel Stockis, Massimo Bani	6
7	Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action 2015 ·Epilepsia ·Jean‐Marie Nicolas, Jonas Hannestad, Daniel Holden, Sophie Kervyn, Nabeel Nabulsi, D. Tytgat, Yiyun Huang, Hugues Chanteux, Ludovicus Staelens, Alain Matagne, François‐Xavier Mathy, Joël Mercier, Armel Stockis, Richard E. Carson, Henrik Klitgaard	123
8	Development of lacosamide for the treatment of partial‐onset seizures 2013 ·Annals of the New York Academy of Sciences ·Pamela Doty, David Hébert, François‐Xavier Mathy, (unknown), (unknown), (unknown)	46
9	Drug metabolism and pharmacokinetics 2009 ·Drug Metabolism Reviews ·M. Strolin Benedetti, Rhys Whomsley, Italo Poggesi, Willi Cawello, François‐Xavier Mathy, Marie‐Laure Delporte, Peggy Papeleu, Jean‐Baptiste Watelet	112
10	In Vivo Methods for the Assessment of Topical Drug Bioavailability 2007 ·Pharmaceutical Research ·Christophe Herkenne, Ingo Alberti, Aarti Naik, Yogeshvar N. Kalia, François‐Xavier Mathy, Véronique Préat, Richard H. Guy	192
11	Stereoselective renal tubular secretion of levocetirizine and dextrocetirizine, the two enantiomers of the H₁‐antihistamine cetirizine 2007 ·Fundamental and Clinical Pharmacology ·M. Strolin Benedetti, Rhys Whomsley, François‐Xavier Mathy, (unknown), Pascal Espié, (unknown)	19
12	Fluconazole Distribution in Rat Dermis Following Intravenous and Topical Application: A Microdialysis Study 2005 ·Journal of Pharmaceutical Sciences ·François‐Xavier Mathy, (unknown), Roger K. Verbeeck, Véronique Préat	35
13	Study of the Percutaneous Penetration of Flurbiprofen by Cutaneous and Subcutaneous Microdialysis after Iontophoretic Delivery in Rat 2004 ·Journal of Pharmaceutical Sciences ·François‐Xavier Mathy, Catherine Lombry, Roger K. Verbeeck, Véronique Préat	8
14	In vivo Tolerance Assessment of Skin after Insertion of Subcutaneous and Cutaneous Microdialysis Probes in the Rat 2003 ·Skin Pharmacology and Physiology ·François‐Xavier Mathy, (unknown), Benoı̂t Vroman, Peter Clarys, André Barel, Roger K. Verbeeck, Véronique Préat	15
15	On-line determination of fluconazole in blood and dermal rat microdialysates by microbore high-performance liquid chromatography 2003 ·Journal of Chromatography B ·François‐Xavier Mathy, Benoı̂t Vroman, (unknown), (unknown), Roger K. Verbeeck, Véronique Préat	35
16	Validation of subcutaneous microdialysis sampling for pharmacokinetic studies of flurbiprofen in the rat 2001 ·Journal of Pharmaceutical Sciences ·François‐Xavier Mathy, Véronique Préat, Roger K. Verbeeck	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact